IO Biotech, Inc. (IOBT)
NASDAQ: IOBT · IEX Real-Time Price · USD
1.580
+0.210 (15.33%)
At close: Jul 19, 2024, 4:00 PM
1.630
+0.050 (3.16%)
Pre-market: Jul 22, 2024, 7:01 AM EDT
IO Biotech Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for IO Biotech stock have an average target of 9.67, with a low estimate of 7.00 and a high estimate of 12. The average target predicts an increase of 512.03% from the current stock price of 1.58.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 15, 2024.
Analyst Ratings
The average analyst rating for IO Biotech stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $12 | Strong Buy | Maintains | $8 → $12 | +659.49% | May 15, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +406.33% | Mar 6, 2024 |
Piper Sandler | Piper Sandler | Buy Initiates $10 | Buy | Initiates | $10 | +532.91% | Sep 28, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +406.33% | Sep 13, 2023 |
Morgan Stanley | Morgan Stanley | Buy Maintains $11 → $7 | Buy | Maintains | $11 → $7 | +343.04% | Aug 15, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
2.04M
EPS This Year
-1.28
from -1.98
EPS Next Year
-1.37
from -1.28
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | n/a | 6.3M | 53.0B | 137.5M | 256.1M |
Avg | n/a | 2.0M | 17.2B | 89.9M | 187.0M |
Low | n/a | n/a | 29.1M | 60.0M | 122.8M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | 2,599,752.9% | -99.2% | 184.8% |
Avg | - | - | 842,792.2% | -99.5% | 107.9% |
Low | - | - | 1,326.9% | -99.7% | 36.6% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -1.12 | -1.20 | -1.05 | -0.82 | -0.39 |
Avg | -1.28 | -1.37 | -1.48 | -0.80 | -0.38 |
Low | -1.36 | -1.61 | -1.94 | -0.76 | -0.36 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.